Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer

Pierre Fabre Medicament459 enrolled

Overview

For patients relapsing after platinum-based therapy, few data are available. The current use of cetuximab associated with radiotherapy in localized disease and associated with platinum-based chemotherapy in the first-line setting stresses the need for new therapeutic options at later stages of SCCHN.Vinca-alkaloids demonstrated activity in SCCHN. Vinflunine demonstrated superior antitumour activity to vinorelbine in preclinical animal models. Recent preliminary phase I results of the vinflunine plus methotrexate combination in SCCHN, based on a clinical review, show encouraging antitumour activity and an acceptable safety profile. Therefore the combination of vinflunine and methotrexate appears a promising salvage regimen after platinum failure. The present study has been designed as a multicenter, randomised phase III study which will compare the combination of IV vinflunine with methotrexate to methotrexate alone in SCCHN patients having failed platinum-based therapy.

This study was designed to compare the OS of VFL plus MTX versus MTX alone in patients with SCCHN who had failed platinum-based chemotherapy. The trial was designed in accordance with current standards used routinely in oncology phase III trials and used established methods of assessment. The RECIST (version 1.1) and NCI CTCAE (version 3.0) guidelines are internationally recognised methods for assessing efficacy and tolerance, respectively. The patient population was appropriate for this type of phase III study and included adult patients with recurrent and/or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, who had received prior chemotherapy regimens with documented progression. This population of patients was considered appropriate to meet the study objectives. Recent preliminary phase I results of the VFL plus MTX combination in SCCHN, reported in a clinical review, showed encouraging antitumour activity and an acceptable safety profile A number of chemotherapy agents have been reported as having single-agent activity in SCCHN. However, reliable evidence of efficacy in the second-line setting is lacking, and there is currently no established standard of care. MTX used alone as the reference regimen at a dose of 40 mg/m2/week can be considered as the best available evidence-based option. Also, other trials using this comparator have demonstrated that it is generally accepted as a reasonable choice, and is often used in general practice. The efficacy and safety assessments employed in this study are standard measures routinely used in studies of this type

Study Type

INTERVENTIONAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed recurrent and/or metastatic squamous cell carcinoma * Documented progressive disease after chemotherapy for locoregionally advanced or recurrent/metastatic SCCHN which included a platinum derivative * Measurable or non measurable disease * adequate haematological, hepatic and renal functions * WHO performance status \< 1 Exclusion Criteria: * Nasopharyngeal carcinoma * History of brain or leptomeningeal involvement * Albumin level \< 35 g/L * Patients with weight loss ≥ 5% within the last 3 months * Grade \> 2 peripheral neuropathy at study entry * "Third space" fluids (pleural effusion, ascites, massive edema) * Prior treatment with vinca-alkaloids and methotrexate

Outcomes

Primary Outcomes

Overall Survival in the ITT Population (Months)

Time from randomization to the date of death or last follow-up. The survival duration of patients still alive, was censored at the date of last contact or last follow-up.

Time frame: Participants will be followed till death (if they are not lost for follow-up), an expected average of 7.5 months

Secondary Outcomes

Progression Free Survival

Time measured from the date of randomisation until date of progression or death from any cause (whichever came first)

Time frame: an expected average of 4 months

Objective Response Rate (ORR)

The objective response is defined as the best response designation recorded across all time points from the date of randomisation until disease progression.

Time frame: 6 weeks

Disease Control Rate

Percentage of best overall responses CR, PR and SD in the analysed population

Time frame: 30 months

Duration of Response

Duration of objective response will be measured for responders (CR+PR) from the time for CR or PR until the 1st date of documentation of recurrent or progressive disease or the date of death any cause.